Finally, genetic alterations such as ERBB2 amplification and functionally relevant mutations in oncogenes and tumor suppressor genes were found in 35.0 and 60.0% of patients, respectively, which is in accordance with the literature.12 This may cause ADT resistance by activating other tumor‐driving pathways, such as the PI3K‐AKT pathway, in the presence of an active AR pathway. The gene discussed is ERBB2; the disease is neoplasm.